VEGFA and cancer: Such preclinical studies evaluating the efficacy of dual inhibition of VEGF and ANG2 provide evidence for the simultaneous inhibition of VEGF and ANG2 as a potential treatment strategy to increase the therapeutic efficacy of immunotherapy, including ICIs in cancer treatment (Figure 3) [108,122].